Core Viewpoint - Shenghe Biotechnology-B (02898.HK) reported a significant increase in other income and a reduction in R&D expenses, but also experienced a rise in losses for the six months ending June 30, 2025 compared to the same period in 2024 [1] Financial Performance - Other income increased by 178% from approximately RMB 1.8 million for the six months ending June 30, 2024 to approximately RMB 5.0 million for the reporting period, primarily due to increased interest income from financial institutions [1] - R&D expenses decreased from approximately RMB 37.7 million in the first half of 2024 to approximately RMB 28.8 million in the reporting period, mainly due to a reduction in share-based compensation [1] - Losses for the period increased from approximately RMB 36.1 million for the six months ending June 30, 2024 to approximately RMB 38.2 million for the reporting period [1]
盛禾生物-B(02898.HK)中期亏损增加至约3820万元